Weybosset Research & Management LLC lifted its holdings in Livent Corporation (NYSE:LTHM) by 39.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,308 shares of the company’s stock after purchasing an additional 32,882 shares during the quarter. Livent comprises about 0.4% of Weybosset Research & Management LLC’s portfolio, making the stock its 26th biggest position. Weybosset Research & Management LLC owned approximately 0.08% of Livent worth $778,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. Point72 Hong Kong Ltd purchased a new position in shares of Livent in the 2nd quarter valued at about $28,000. Coastal Investment Advisors Inc. boosted its stake in shares of Livent by 126.7% in the 2nd quarter. Coastal Investment Advisors Inc. now owns 5,123 shares of the company’s stock valued at $35,000 after purchasing an additional 2,863 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Livent in the 1st quarter valued at about $52,000. Tower Research Capital LLC TRC bought a new position in shares of Livent in the 2nd quarter valued at about $59,000. Finally, Sigma Planning Corp bought a new position in shares of Livent in the 2nd quarter valued at about $77,000. 98.06% of the stock is owned by hedge funds and other institutional investors.
Shares of Livent stock traded down $0.02 on Tuesday, hitting $7.03. The company’s stock had a trading volume of 14,481 shares, compared to its average volume of 1,423,636. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.11 and a current ratio of 2.85. Livent Corporation has a 1 year low of $5.49 and a 1 year high of $19.90. The firm has a fifty day moving average price of $6.82 and a 200-day moving average price of $7.67. The company has a market capitalization of $1.03 billion and a price-to-earnings ratio of 7.74.
Several research analysts have recently issued reports on LTHM shares. Zacks Investment Research lowered shares of Livent from a “hold” rating to a “sell” rating in a research note on Thursday, October 10th. Bank of America lowered Livent from a “neutral” rating to an “underperform” rating and dropped their price target for the company from $10.00 to $7.00 in a research note on Monday, August 12th. Nomura set a $9.00 price target on Livent and gave the company a “hold” rating in a research note on Wednesday, August 7th. ValuEngine raised Livent from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, Citigroup dropped their price target on Livent from $8.25 to $7.50 and set a “neutral” rating for the company in a research note on Wednesday, October 9th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company’s stock. Livent has an average rating of “Hold” and a consensus target price of $15.08.
Livent Corporation manufactures and sells performance lithium compounds that are used primarily in energy storage, specialty polymers, and chemical synthesis application. The company offers lithium compounds for use in applications that have specific performance requirements, including battery-grade lithium hydroxide for use in high performance lithium-ion batteries; and supplies butyllithium, which is used as a synthesizer in the production of polymers and pharmaceutical products, as well as a range of specialty lithium compounds, including high purity lithium metal, which is used in the production of lightweight materials for aerospace applications and non-rechargeable batteries.
Receive News & Ratings for Livent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Livent and related companies with MarketBeat.com's FREE daily email newsletter.